Current Clinical Trials

How to Participate/Find a Trial

If you want to discuss clinical research trials, and you are already a patient, ask your provider at your next visit. Alternatively, or If you are not a current patient, you can call the HOA Research Department at 315-472-7504, extension 1350.

A list of HOA’s current clinical trials that are recruiting new patients is below. The list is grouped by disease.

If you are looking for a trial that is not listed here, please contact us as we may be able to open a trial for eligible patients. 

For a complete list of all available clinical trials nationwide, visit, a website maintained by the National Insitutes of Health -- which is the research arm of the Department of Health and Human Services.


Breast, A011801

CompassHer2 Residual Disease (RD): Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Breast, Ascent 03

Trodelvy vs MD Choice for Untreated PD-L1 Negative mTNBC or PD-L1 Positive Previously Treated w/ Anti PD-L1 Therapy Who Recur

Breast, ASCENT-05/ GS-US-595-6184/ AFT-65

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Breast, Cambria 1 D8531C00002

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Breast, Cambria-2 D8535C00001

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).

Breast, CELC-G-301

Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer

Breast, D8534C00001 “SERENA-6”

Phase III Study to Assess AZD9833+ CDK4/​6 Inhibitor in HR+/​HER2-MBC with Detectable ESR1m Before Progression

Breast, NRG-BR007

DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18

Breast, OptimICE-pCR: A012103

This phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab.

Breast, Pfizer-C4891001

VERITAC-2- Open-Label Trial of ARV-471 (PF-07850327) vs. Fulvestrant in PTS W/ ER-Positive, HER2-Negative Advanced Breast Cancer w/ Disease Progression After Prior Endocrine Rx For Advanced Disease

Breast, TOL2506A

Ovarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), S1925

Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with CLL/SLL


Colorectal, A221805

This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.


Esophageal, MK-7902-014

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)


Immunotherapy, A151804

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects


Kidney, A031704

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study


Lung, A081801

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study

Lung, A151216

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Lung, AFT-57

This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.

Lung, D926NC0001 “AVANZAR”

Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations

Lung, NRG-LU007

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

Lung, S1827

Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer (MAVERICK)

Myeloid Diseases (Primary Myelofibrosis, Myelodysplastic Syndrome, Acute Myeloid Leukemia)

Myeloid Diseases (Primary Myelofibrosis, Myelodysplastic Syndrome, Acute Myeloid Leukemia), AZA-MDS-006

Connect MDS and AML Registry

Solid Tumor

Advanced and Metastatic Solid Tumors, IMM-1-104

This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.

Multiple Myeloma

Multiple Myeloma, Equate EAA181

Effective Quadruplet Utilization after Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation.